PADI4 and rheumatoid arthritis: Serum anti-PAD4 IgG from some patients with RA has been shown to modulate the catalytic activity of PAD4 [3, 19], with a subset of patients possessing IgG with the capacity to augment the ability of PAD4 to citrullinate substrates.